Amer M. Mirza

Amer Mirza is a drug discovery and development executive with 20 years of experience at small and large biopharmaceutical companies, focusing on innovative and differentiated small molecule and biologics drug development. His broad experience spans target identification, therapeutic discovery, translational research, and clinical development across diverse disease areas including metabolic, oncology, immuno-oncology, inflammation/immunology and endocrine indications.

Prior to joining Septerna, Amer served as Vice President, Biomarker Discovery and Development at Ascendis Pharma; as Head of Inflammation Biomarkers at Gilead Sciences; and as Head of Disease Biology and Translational Medicine at XOMA. Experienced in building innovative and impactful cross-functional teams, Amer served in leadership roles advancing discovery, preclinical, and clinical development programs filing over 12 INDs and 4 NDAs/BLA. While at Gilead, he served on the Global Development and Launch Team for filgotinib, an approved oral JAK1 inhibitor.

Amer received his PhD from the University of Toronto and completed his post-doctoral fellowship at DNAX Research Institute and UCSF Cancer Center.